E. Blair Holladay, PhD., SCT(ASCP), CM

Topic:

“The Role of p16 oncogene in the Progression of Cervical Neoplasia: the Pros and Cons of Molecular Biomarkers”

When:

Monday, January 7, 2008
12:00PM – 1:00PM
 

Location:

BALDWIN AUDITORIUM, LURIE BUILDING
  

Hosted by Ritu Nayar , MD

Holladay EB, Logan S, Arnold J, Knesel B, Smith GD.  A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer.  2006 Oct 31; [Epub ahead of print].

Castle PE, Sadorra M, Garcia F, Holladay EB, Kornegay J.  Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology.  J Clin Microbiol. 2006 Nov;44(11):3915-7. Epub 2006 Sep 13.  [PubMed - in process].

Renshaw AA, Holladay EB, Geils KB.  Results of multiple-slide, blinded review of Papanicolaou slides in the context of litigation.  Determining what can be detected regularly and reliably.  Cancer; 2005 Oct 25;105(5):263-9.

Castle PE, Garcia-Meijide M, Holladay EB, Chuke R, Payne J, Long A, Siefers H, Demuth F, Lorincz AT.  A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II.  Am J Clin Pathol. 2005 Feb;123(2):250-5.

Renshaw AA, Young ML, Holladay EB.  Blinded review of Papanicolaou smears in the context of litigation.  Cancer 2004 Jun 25;102(3):136-41.

Holladay EB, Allen KA.  A new era for the Pap test.  JAAPA 2001 Dec;14(12):53-6.

Bacro TR, Holladay EB, Stith MJ, Maize JC, Smith CM.  Iontophoresis treatment of basal cell carcinoma with cisplatin: a case report.  Cancer Detect Prev 2000;24(6):610-9.